ESTRO 2021 | 2-year toxicity update in PACE-B for localised prostate cancer

Alison Tree • 3 Sep 2021

ESTRO 2021

PACE-B

Alison Tree, BSc, MBBS, FRCR, MD(res), The Royal Marsden NHS Foundation Trust, London, UK, gives an update on the 2-year toxicity data of the PACE-B trial (NCT01584258) comparing hypofractionated stereotactic body radiotherapy (SBRT) to conventional radiotherapy in men with localized prostate cancer. 874 patients were randomly assigned 1:1 to either conventional radiotherapy (62 Gy in 20 fractions or 78 Gy in 39 fractions) or SBRT (36.25 Gy in 5 fractions). The data shows that long-term toxicity is very similar between the two groups, with no difference seen in terms of bowel toxicity and a slightly higher bladder toxicity for patients enrolled in the SBRT treatment arm. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2021.